Latest oppositions filed by Genmab A/s

This table presents recent patent oppositions filed by Genmab A/s against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP3656443Use Of Trl Agonist And Anti-Cd47 Agent To Enhance Phagocytosis Of Cancer CellsTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJun 29, 2022
EP3177645Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFER, HORST, DR.Nov 17, 2021
EP3056514Methods For Manipulating Phagocytosis Mediated By Cd47THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 17, 2020
EP3056515Methods For Manipulating Phagocytosis Mediated By Cd47THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 17, 2020
EP2970493Methods For Achieving Therapeutically Effective Doses Of Anti-Cd47 AgentsTHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYJan 3, 2020
EP2647707Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAJun 12, 2019

The following table provides an overview of the latest patents of Genmab A/s that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3319996Jan 3, 2024Bispecific And Multispecific Antibodies And Method For Isolation Of Such2
EP2943507Feb 26, 2020Inert Format2
EP3312196Jul 17, 2019Antibodies Against Cd38 For Treatment Of Multiple Myeloma1
EP2535355Jan 2, 2019Antibodies Against Cd38 For Treatment Of Multiple Myeloma1
EP2076769Apr 25, 2018High Througput Methods For Characterization Of Antibodies1